# IDeate-Esophageal01 (NCT06644781)

> A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

No report yet. It can be ordered.

- Drugs tested: ifinatamab deruxtecan
- Indication: pretreated advanced or metastatic esophageal squamous cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06644781
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Esophageal Squamous Cell Carcinoma
- Interventions: Ifinatamab deruxtecan; Docetaxel; Paclitaxel; Irinotecan hydrochloride (HCl)
- Enrollment: 510
- Primary outcome: Overall Survival (OS)

## Indexed commentary on IDeate-Esophageal01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ideate-esophageal01-nct06644781